Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2018 | Original Article

Up-front PET/CT changes treatment intent in patients with head and neck squamous cell carcinoma

Authors: Max Rohde, Anne L. Nielsen, Jørgen Johansen, Jens A. Sørensen, Anabel Diaz, Jon T. Asmussen, Oke Gerke, Anders Thomassen, Niels Gyldenkerne, Helle Døssing, Kristine Bjørndal, Poul Flemming Høilund-Carlsen, Christian Godballe

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2018

Abstract

Purpose

In patients with newly diagnosed head and neck squamous cell carcinoma (HNSCC), we wanted to examine the differences in overall treatment decisions, i.e. curative versus palliative treatment intent, reached by a multidisciplinary team conference (MDTC) based on 18F–fluoro-deoxy-glucose-positron emission tomography/computed tomography (PET/CT) or chest X-ray + MRI of the head and neck (CXR/MRI).

Patients and methods

This was a prospective blinded cohort study based on paired data. Consecutive patients with histologically verified primary HNSCC were invited to participate. All included patients underwent CXR/MRI and PET/CT before diagnostic biopsy. An ordinary MDTC using all available imaging was conducted as per standard practice. After at least 3 months (to eliminate recall bias in the team), the first project MDTC was conducted, based on either CXR/MRI or PET/CT, and the tumor board drew conclusions regarding treatment. After an additional 3 months, a second project MDTC was conducted using the complementary imaging modality.

Results

A total of 307 patients were included. Based on CXR/MRI, 303 patients (99%) were recommended for curative treatment and only four patients (1%) for palliative treatment. Based on PET/CT, the MDTC concluded that 278 (91%) patients were suitable for curative treatment and 29 (9%) patients for palliative treatment. The absolute difference of 8% was statistically significant (95% CI: 4.8%–11.5%, p < 0.001).

Conclusions

A PET/CT-based imaging strategy significantly changed the decisions regarding treatment intent made by a MDTC for patients diagnosed with HNSCC, when compared with the standard imaging strategy of CXR/MRI.

Available only for authorised users

Rohde M, Dyrvig AK, Johansen J, Sorensen JA, Gerke O, Nielsen AL, et al. 18F–fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Europe J Cancer (Oxford, England : 1990). 2014;50:2271–9. https://doi.org/10.1016/j.ejca.2014.05.015.

Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28:1190–5. https://doi.org/10.1200/jco.2009.24.6298.CrossRef

Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clin Oncol (Royal College of Radiologists (Great Britain)). 2013;25:e33–66. https://doi.org/10.1016/j.clon.2012.08.007.CrossRef

Cacicedo J, Fernandez I, Del Hoyo O, Dolado A, Gomez-Suarez J, Hortelano E, et al. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis. Eur J Nucl Med Mol Imaging. 2015;42:1378–89. https://doi.org/10.1007/s00259-015-3071-0.CrossRefPubMed

Senft A, de Bree R, Hoekstra OS, Kuik DJ, Golding RP, Oyen WJ, et al. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol. 2008;87:221–9. https://doi.org/10.1016/j.radonc.2008.03.008.CrossRefPubMed

Haerle SK, Schmid DT, Ahmad N, Hany TF, Stoeckli SJ. The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol. 2011;47:653–9. https://doi.org/10.1016/j.oraloncology.2011.05.011.CrossRefPubMed

Xu GZ, Guan DJ, He ZY. (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis. Oral Oncol. 2011;47:560–5. https://doi.org/10.1016/j.oraloncology.2011.04.021.CrossRefPubMed

Johansen J, Petersen H, Godballe C, Loft A, Grau C. FDG-PET/CT for detection of the unknown primary head and neck tumor. Quarter J Nucl Med Molec Imaging. 2011;55:500–8.

Krabbe CA, Pruim J, van der Laan BF, Rodiger LA, Roodenburg JL. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. Oral Oncol. 2009;45:234–40. https://doi.org/10.1016/j.oraloncology.2008.05.024.CrossRefPubMed

10.

Kim SY, Roh JL, Yeo NK, Kim JS, Lee JH, Choi SH, et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol. 2007;18:1698–703. https://doi.org/10.1093/annonc/mdm270.CrossRefPubMed

11.

Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v184–v6.CrossRefPubMed

12.

Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nuclear Med : Off Publ, Soc Nucl Med. 2008;49:1593–600. https://doi.org/10.2967/jnumed.108.053660.CrossRef

13.

Arias F, Chicata V, Garcia-Velloso MJ, Asin G, Uzcanga M, Eito C, et al. Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer. Clin Translat Oncol : Off Publ Fed Spanish Oncol Soc National Cancer Instit Mexico. 2015;17:139–44. https://doi.org/10.1007/s12094-014-1204-8.CrossRef

14.

Abramyuk A, Appold S, Zophel K, Baumann M, Abolmaali N. Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2013;189:197–201. https://doi.org/10.1007/s00066-012-0283-0.CrossRef

15.

Prestwich RJ, Bhatnagar P, Chowdhury FU, Patel CN, Dyker KE, Coyle C, et al. The impact of (18)F-FDG PET CT prior to Chemoradiotherapy for stage III/IV head and neck Squamous cell carcinoma. ISRN Oncol. 2012;2012:636379. https://doi.org/10.5402/2012/636379.PubMedPubMedCentral

16.

Paidpally V, Tahari AK, Lam S, Alluri K, Marur S, Koch W, et al. Addition of 18F–FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years. J Nucl Med : Off Publ, Soc Nucl Med. 2013; https://doi.org/10.2967/jnumed.113.121285.

17.

Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173–9. https://doi.org/10.1097/MLG.0b013e31805d017b.CrossRefPubMed

18.

Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29:986–95. https://doi.org/10.1002/hed.20629.CrossRefPubMed

19.

Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope. 2005;115:1186–90.CrossRefPubMed

20.

Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol0--Head Neck Surg. 2006;132:12–6. https://doi.org/10.1001/archotol.132.1.12.CrossRef

21.

Ryu IS, Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, et al. Impact of (18)F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study. Europe J Cancer (Oxford, England : 1990). 2016;63:88–96. https://doi.org/10.1016/j.ejca.2016.05.002.

22.

Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg (London, England). 2014;12:1500–24. https://doi.org/10.1016/j.ijsu.2014.07.014.CrossRef

23.

Rohde M, Nielsen AL, Johansen J, Sorensen JA, Diaz A, Asmussen JT, et al. Head-to-head comparison of chest x-ray/head and neck MRI, chest CT/head and neck MRI, and 18F–FDG-PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal Cancer. J Nucl Med : Off Publ, Soc Nuclear Med. 2017; https://doi.org/10.2967/jnumed.117.189704.

24.

Greenland P. Comments on 'Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond' by M. J. Pencina, R. B. D'Agostino Sr, R. B. D'Agostino Jr, R. S. Vasan, statistics in medicine (DOI: 10.1002/sim.2929). Stat Med. 2008;27:188–90. https://doi.org/10.1002/sim.2976.CrossRefPubMed

25.

Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172; discussion 207-12. https://doi.org/10.1002/sim.2929.CrossRefPubMed

26.

Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928–35. https://doi.org/10.1161/circulationaha.106.672402.CrossRefPubMed

27.

Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol--Head Neck Surg : Off J Am Acad Otolaryngol-Head Neck Surg. 2007;137:130–7. https://doi.org/10.1016/j.otohns.2007.02.001.CrossRef

28.

Gerke O, Hermansson R, Hess S, Schifter S, Vach W, Hoilund-Carlsen PF. Cost-effectiveness of PET and PET/computed tomography: a systematic review. PET Clin. 2015;10:105–24. https://doi.org/10.1016/j.cpet.2014.09.008.CrossRefPubMed

29.

Gerke O, Hoilund-Carlsen PF, Poulsen MH, Vach W. Interim analyses in diagnostic versus treatment studies: differences and similarities. Am J Nucl Med Mol Imaging. 2012;2:344–52.PubMedPubMedCentral

30.

Siepe B, Hoilund-Carlsen PF, Gerke O, Weber WA, Motschall E, Vach W. The move from accuracy studies to randomized trials in PET: current status and future directions. J Nucl Med : Off Publ, Soc Nucl Med. 2014;55:1228–34. https://doi.org/10.2967/jnumed.113.127076.CrossRef

31.

Vach W, Hoilund-Carlsen PF, Gerke O, Weber WA. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med : Off Publ, Soc Nucl Med. 2011;52(Suppl 2):77S–85S. https://doi.org/10.2967/jnumed.110.085704.CrossRef

32.

Gerke O, Hoilund-Carlsen PF, Vach W. Analyzing paired diagnostic studies by estimating the expected benefit. Biom J. 2015;57:395–409. https://doi.org/10.1002/bimj.201400020.CrossRefPubMed

Title: Up-front PET/CT changes treatment intent in patients with head and neck squamous cell carcinoma
Authors: Max Rohde
Anne L. Nielsen
Jørgen Johansen
Jens A. Sørensen
Anabel Diaz
Jon T. Asmussen
Oke Gerke
Anders Thomassen
Niels Gyldenkerne
Helle Døssing
Kristine Bjørndal
Poul Flemming Høilund-Carlsen
Christian Godballe
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3873-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Up-front PET/CT changes treatment intent in patients with head and neck squamous cell carcinoma

Abstract

Purpose

Patients and methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method

FDG PET-CT as a powerful tool for diagnosing and monitoring treatment outcomes of relapsing polychondritis

Impact of initial myocardial perfusion imaging versus invasive coronary angiography on outcomes in coronary artery disease: a nationwide cohort study

Preclinical evaluation of an 18F-trifluoroborate methionine derivative for glioma imaging

Combined evaluation of regional coronary artery calcium and myocardial perfusion by 82Rb PET/CT in the identification of obstructive coronary artery disease

Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers